GSK (NYSE:GSK) has initiated an appeal process against a recent Delaware Superior Court decision in the ongoing Zantac (ranitidine) litigation.

The company challenges the court's ruling to allow plaintiff expert testimony, arguing it is inconsistent with the Daubert standard as previously applied in Delaware and federal courts.

An application has been filed to seek the right of appeal to the Delaware Supreme Court.

Pfizer, Sanofi, and Boehringer Ingelheim have also joined the appeal process.

GSK emphasizes that the scientific consensus remains unchanged: there is no consistent or reliable evidence linking ranitidine to an increased risk of any cancer.

The company points to 16 epidemiological studies that support this position.

The Delaware Supreme Court is expected to decide on the application for interlocutory review later this year.